Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Corporate Presentation Corporate Fact Sheet

Latest News

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

January 12, 2023

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform

January 5, 2023

IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

December 14, 2022

Financial Events

Imunon, Inc. Third Quarter 2022 Earnings Call

November 14, 2022 at 11:00 AM EST

Imunon Corporation Presentation_Chardan’s 6th Annual Genetic Medicines Conference

October 3, 2022 at 2:30 PM EDT